Bisphenol A and carcinogenesis

Regarding "A Ban on Estrogenics?"1 we must be wary also about a possible cancer risk from long-term exposure to bisphenol A (BP-A) and other estrogenic endocrine disruptors as well. Steroidal/non-steroidal and postmenopausal estrogens and diethylstilbestrol (DES) as examples at low doses are long-known human carcinogens.2 In 1980, the National Toxicology Program in public session reported on the carcinogenicity of BP-A.3 With renewed emphasis on endocrine disruptors,4 we decided our bioassay fin

Written byJames Huff
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Regarding "A Ban on Estrogenics?"1 we must be wary also about a possible cancer risk from long-term exposure to bisphenol A (BP-A) and other estrogenic endocrine disruptors as well. Steroidal/non-steroidal and postmenopausal estrogens and diethylstilbestrol (DES) as examples at low doses are long-known human carcinogens.2 In 1980, the National Toxicology Program in public session reported on the carcinogenicity of BP-A.3 With renewed emphasis on endocrine disruptors,4 we decided our bioassay findings should be made more widely available.5

Overall, the NTP concluded that while the evidence of carcinogenicity was not fully convincing, marginal increases in leukemias in male and female rats, along with increases in the combined incidence of lymphomas and leukemias in male mice, suggest that BP-A may be associated with increased cancers of the hematopoietic system. Increases in interstitial-cell tumors of the testes in rats were also evidence of carcinogenesis, as was the unusual occurrence of mammary gland fibroadenomas ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies